New Reflex Testing Streamlines Hepatitis D Detection in High-Risk Patients
A new reflex testing pathway for hepatitis D virus (HDV) has been implemented for patients positive for hepatitis B surface antigen, revealing that 8.3% of such individuals were also infected with HDV. This approach mirrors successful models used in hepatitis C screening and aims to improve early detection and management of co-infections. The strategy could significantly enhance outcomes by identifying HDV earlier in the disease course.
A new reflex testing pathway for hepatitis D virus (HDV) has been introduced for patients who test positive for hepatitis B surface antigen (HBsAg), revealing that 8.3% of these individuals were also co-infected with HDV. This approach, implemented as a standard follow-up in high-risk populations, mirrors prior successful models used in hepatitis C screening, where confirmatory testing is automatically triggered upon initial positive results. The strategy aims to improve early detection and management of HDV, which is known to accelerate liver disease progression when present alongside hepatitis B. By integrating HDV testing into the existing HBsAg-positive workflow, clinicians can identify co-infections earlier in the disease course, potentially altering long-term outcomes.
The development builds on prior efforts to streamline viral hepatitis screening, particularly the established reflex testing protocols for hepatitis C that have significantly improved detection rates and treatment initiation. While the material does not specify the exact institution or region where this new pathway was implemented, it implies a broader public health shift toward proactive co-infection screening in high-risk groups. The initiative reflects growing recognition of HDV as a significant contributor to liver morbidity and mortality, especially among those with chronic hepatitis B. Organizations involved likely include public health agencies, infectious disease specialists, and clinical laborat
This new reflex testing approach could significantly improve early detection of hepatitis D in a population already at elevated risk—those with chronic hepatitis B—potentially reducing liver-related complications and deaths. By leveraging an established model from hepatitis C screening, the strategy may serve as a template for integrating additional viral co-infection tests into routine diagnostics. If widely adopted, it could shift clinical practice toward more comprehensive viral hepatitis management, particularly in regions with high HBV prevalence such as parts of Asia and sub-Saharan Africa. The broader impact may extend to public health systems, which could see reduced burden from advanced liver disease through earlier interventions. It may also influence pharmaceutical markets, where treatments for HDV—though limited—are under development; earlier diagnosis could increase demand for effective therapies. A comparable precedent is the rollout of hepatitis C reflex testing in the